Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Bristol Myers Soars, But Future Clouds | Raleigh News
Bristol Myers Squibb’s Q2 earnings beat expectations, lifting its stock as Eliquis—its blockbuster blood thinner with Pfizer—shows stronger-than-expected sales growth. But Morgan Stanley remains bearish, holding an “Underweight” rating and a $40 price target, citing looming patent expirations and delayed pipeline drugs like Milvexian and Cobenfy that could stall future growth. While the company shines now with solid dividends and near-term profits, investors are divided on whether its pipeline can sustain momentum beyond the patent cliff. Listen in comfort:Get a discount on a Soli Pillow…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.